DDInter1258 DDInter782
Naldemedine is an opioid receptor antagonist [FDA Label]. It is a modified form of to which a side chain has been added to increase molecular weight and polar surface area resulting in restricted transport across the blood brain barrier. Naldemedine was approved in 2017 in both the US and Japan for the treatment of Opioid-induced Constipation.
In April 2018, the U.S. Food and Drug Administration (FDA) and the Swiss company Helsinn approved the intravenous formulation of AKYNZEO® (NEPA, a fixed antiemetic combination of fosnetupitant, 235mg, and palonosetron, 0.25mg) as an alternative treatment option for patients experiencing chemotherapy-induced nausea and vomiting . Fosnetupitant is the pro-drug form of netupitant [FDA label]. Generally, 25% to 30% of patients with a diagnosis of cancer receive chemotherapy as a treatment modality and 70% to 80% of these patients undergoing chemotherapy treatment may experience nausea and vomiting as major side effects. Considered one of the most distressing side effects of chemotherapy, nausea and vomiting has an immense impact on the quality of life of patients receiving certain antineoplastic therapies .
Naldemedine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Modafinil
Naldemedine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Mifepristone
Naldemedine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Istradefylline
Naldemedine {u} may lead to a major life threatening interaction when taken with {v} Phenobarbital
Naldemedine {u} may lead to a major life threatening interaction when taken with {v} Apalutamide
Naldemedine may cause a minor interaction that can limit clinical effects when taken with Modafinil
Naldemedine may cause a moderate interaction that could exacerbate diseases when taken with Mifepristone
Naldemedine may cause a moderate interaction that could exacerbate diseases when taken with Istradefylline
Naldemedine may lead to a major life threatening interaction when taken with Phenobarbital
Naldemedine may lead to a major life threatening interaction when taken with Apalutamide